Chimeric Therapeutics Limited (CHM.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 04:10PM AEST
| Previous close | 0.0180 |
| Open | 0.0180 |
| Bid | 0.0170 x 24502200 |
| Ask | 0.0180 x 16334300 |
| Day's range | 0.0170 - 0.0180 |
| 52-week range | 0.0160 - 0.0470 |
| Volume | |
| Avg. volume | 2,333,382 |
| Market cap | 15.529M |
| Beta (5Y monthly) | 1.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings date | 30 Aug 2024 - 03 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS
Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers.
© 2024 Yahoo. All rights reserved.